Drug Type Chemical drugs |
Synonyms |
Target |
Mechanism GHR agonists(Growth hormone receptor agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Molecular FormulaC78H123N23O23S2 |
InChIKeyGVIYUKXRXPXMQM-BPXGDYAESA-N |
CAS Registry221231-10-3 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Lumbar Radiculopathy | Phase 1 | AU | 17 May 2022 | |
Radicular Pain | Phase 1 | AU | 17 May 2022 | |
Diabetic peripheral neuropathy | Phase 1 | AU | 09 Apr 2019 | |
Obesity | Phase 1 | AU | - | |
Acute migraine | Discovery | AU | 24 Sep 2019 | |
Diabetic peripheral neuropathy | Discovery | GB | 09 Apr 2019 | |
Neuralgia, Postherpetic | Discovery | AU | 09 Apr 2019 | |
Neuralgia, Postherpetic | Discovery | GB | 09 Apr 2019 | |
Osteoporosis | Discovery | AU | - | - |
Phase 2 | 53 | (LAT8881) | asquwuczpa(npfjsuknko) = ikogkerqes iyuiyjcbrv (gispjlzkui, trqeggokkb - zxgrhyrlty) View more | - | 23 Apr 2021 | ||
Placebo (Placebo) | asquwuczpa(npfjsuknko) = jaczxnprsj iyuiyjcbrv (gispjlzkui, wuahyoanqt - aoatgyqrwb) View more | ||||||
Phase 2 | 21 | (Active) | ofdjoknnnv(lxvmsqebqt) = uftfhjbaju ttpggyvnxe (ynyhkgxubk, rjxuntsttl - qetglskuof) View more | - | 30 Mar 2021 | ||
Placebo (Placebo) | ofdjoknnnv(lxvmsqebqt) = eiaehbhkho ttpggyvnxe (ynyhkgxubk, xgmmiccjrb - oljtniupap) View more |